000			02890nam a2200301Ia 4500
005			20250223033141.0
008			231030s9999 xx 000 0 und d
049			_aDeposit
082			_a618.842
097			_aPh.D
099			_aCai01.11.22.Ph.D.2022.Em.D.
100			_aEman Ashraf El-Tahery Mousa,
245		4	_aThe diagnostic performance of prostate specific membrane antigen ligands positron emission tomography/computed tomography in patients with biochemically recurrent prostate cancer after radical treatment/ _cBy Eman Ashraf El-Tahery Mousa; Supervision Sherif Mohamed El-Refaei, Mohamed Abdel-Lateef Shahin, Mohamed Mohamed Houseni, Ahmed Essam Tawakol.
246			_aالأداء التشخيصي للمسح الذري البوزيترونى المقطعي المدمج بالأشعة المقطعية بروابط المستضد الغشائي البروستاتي النوعي في الارتجاع الكيميائي لمرضى سرطان البروستاتا بعد العلاج الجذري
260			_c2022.
502			_aThesis (Ph.D)-Cairo University,2022.
504			_aBibliography: p. 206-233.
520			_aOur prospective study included 131 male patients who were referred to our center from March 2020 till March 2022 with proven biochemical recurrent prostatic adenocarcinoma. The patients’ data and images were analyzed for the rate of detection of recurrence based on PROMISE criteria. Also, correlation between serum PSA level and detection rate of PSMA PET/CT was analyzed. Moreover, the PSMA PET/CT was evaluated in relation to the Gleason score (ISUP groups) whenever available and to ADT within 6 months before the scan. Results: The overall detection rate was 102/131 patients (77.8 %). There was positive relation between serum PSA before the scan and the positivity of PSMA PET/CT. Patients were subdivided according to their serum PSA level before the scan in to 5 groups as: <0.2 ng/ml, 0.2-0.5 ng/ml, >0.5-3 ng/ml, >3- 10 ng/ml and >10 ng/ml where the detection rates were 53.3%, 64.3%, 80.4%, 91.3% and 94.7% respectively. The most common sites of recurrence were operative bed/ radiated prostate, pelvic lymph nodes, osseous deposits, retro-peritoneal lymph nodes and visceral deposits. The pathology reports/results were available in 62 patients and our study revealed no relation between positivity of PSMA PET/CT and ISUP pathological groups as well as ADT 6 months prior to the scan. We found that a cutoff value for serum PSA level to differentiate between positive PSMA PET/CT scan from a negative one to be >0.73 ng/ml.
650			_aRadiation therapy.
653			_aPSMA PET/CT.
700			_aSherif Mohamed El-Refaei
856			_uhttp://172.23.153.220/th.pdf
905			_aMohamady
942			_cTH _2ddc
999			_c164867 _d164867
336			_2rda content _atext
337			_2rdamedia _aUnmediated
338			_2rdacarrier _avolume